Cargando…

Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple‐negative breast cancer patients

mRNA profiles of circulating tumour cells (CTCs) were analysed in patients with triple‐negative breast cancer (TNBC) (pts) before (BT) and after therapy (AT) to identify additional treatment options. 2 × 5 mL blood of 51 TNBC pts and 24 non‐TNBC pts (HR+/HER2−; HR−/HER2+) was analysed for CTCs using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bittner, Ann‐Kathrin, Keup, Corinna, Hoffmann, Oliver, Hauch, Siegfried, Kimmig, Rainer, Kasimir‐Bauer, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412423/ https://www.ncbi.nlm.nih.gov/pubmed/32558176 http://dx.doi.org/10.1111/jcmm.15349

Ejemplares similares

Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2020)

Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients
por: Keup, Corinna, et al.
Publicado: (2020)

Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients
por: Keup, Corinna, et al.
Publicado: (2021)

Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients
por: Keup, Corinna, et al.
Publicado: (2019)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
por: Keup, Corinna, et al.
Publicado: (2023)

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Keup, Corinna, et al.
Publicado: (2019)

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2009)

Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse
por: Hoffmann, Oliver, et al.
Publicado: (2022)

Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer
por: Keup, Corinna, et al.
Publicado: (2021)

Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
por: Moukas, Stefanos Ioannis, et al.
Publicado: (2023)

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2012)

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy
por: Chebouti, Issam, et al.
Publicado: (2017)

Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients
por: Hoffmann, Oliver, et al.
Publicado: (2023)

Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2021)

In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2022)

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer
por: Chebouti, Issam, et al.
Publicado: (2016)

Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer
por: König, Lisa, et al.
Publicado: (2019)

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer
por: Bredemeier, Maren, et al.
Publicado: (2017)

Association of Soluble B7-H4 and Circulating Tumor Cells in Blood of Advanced Epithelial Ovarian Cancer Patients
por: Mach, Pawel, et al.
Publicado: (2021)

Systematic Evaluation of HLA-G 3’Untranslated Region Variants in Locally Advanced, Non-Metastatic Breast Cancer Patients: UTR-1, 2 or UTR-4 are Predictors for Therapy and Disease Outcome
por: Rebmann, Vera, et al.
Publicado: (2022)

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
por: Fehm, Tanja, et al.
Publicado: (2009)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis
por: Kallergi, Galatea, et al.
Publicado: (2020)

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival
por: Kuhlmann, Jan Dominik, et al.
Publicado: (2012)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment
por: Bredemeier, Maren, et al.
Publicado: (2016)

Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer
por: Schwich, Esther, et al.
Publicado: (2019)

Image-Based Identification and Genomic Analysis of Single Circulating Tumor Cells in High Grade Serous Ovarian Cancer Patients
por: Salmon, Carolin, et al.
Publicado: (2021)

Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer
por: Jannusch, Kai, et al.
Publicado: (2023)

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2009)

Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
por: Chebouti, Issam, et al.
Publicado: (2016)

Evaluation of a novel ELISA for the tumor-associated antigen CA 72–4 in patients with ovarian cancer
por: Buderath, Paul, et al.
Publicado: (2016)

Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome
por: Köninger, Angela, et al.
Publicado: (2014)

Anti-Mullerian-hormone levels during pregnancy and postpartum
por: Köninger, Angela, et al.
Publicado: (2013)

Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer
por: Strati, Areti, et al.
Publicado: (2013)

HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer
por: Schwich, Esther, et al.
Publicado: (2019)

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response
por: Mairinger, Fabian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t6j8fqlet7fhmpicu39mabvdag